William Pao, Pfizer's departing chief development officer
Pfizer brings oncology R&D leader into C-suite, parts ways with development chief William Pao after just 16 months
Pfizer will shuffle its executive team, emphasizing the role oncology will play in its future by adding a new C-suite member but also parting ways …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
